Loading...
OTCM
NBRVF
Market cap0kUSD
Mar 25, Last price  
0.00USD
Name

Nabriva Therapeutics PLC

Chart & Performance

D1W1MN
P/E
—
P/S
0.00
EPS
—
Div Yield, %
—
Shrs. gr., 5y
86.36%
Rev. gr., 5y
20.25%
Revenues
36m
+31.06%
0084,000006,500,0007,748,0002,864,00027,216,00035,668,000
Net income
-57m
L+15.64%
15,479,57600-54,890,000-74,356,000-114,780,000-82,764,000-69,484,000-49,450,000-57,185,000
CFO
-37m
L-38.36%
000-49,321,000-69,348,000-72,723,000-71,892,000-71,331,000-59,557,000-36,711,000

Profile

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, hospital-acquired bacterial pneumonia, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.
URL
https://www.nabriva.com/
IPO date
Sep 18, 2015
Employees
39
Domiciled in
IE
Incorporated in
IE

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
35,668
31.06%
Cost of revenue
42,844
Unusual Expense (Income)
NOPBT
(7,176)
NOPBT Margin
Operating Taxes
1,568
Tax Rate
NOPAT
(8,744)
Net income
(57,185)
15.64%
Dividends
Dividend yield
Proceeds from repurchase of equity
2,123
BB yield
-41.88%
Debt
Debt current
4,833
Long-term debt
388
Deferred revenue
Other long-term liabilities
479
Net debt
(7,193)
Cash flow
Cash from operating activities
(36,711)
CAPEX
(211)
Cash from investing activities
(263)
Cash from financing activities
1,851
FCF
5,224
Balance
Cash
12,414
Long term investments
Excess cash
10,631
Stockholders' equity
(652,802)
Invested Capital
661,795
ROIC
ROCE
EV
Common stock shares outstanding
2,682
Price
1.89
215.58%
Market cap
5,069
388.11%
EV
(2,124)
EBITDA
(6,959)
EV/EBITDA
0.31
Interest
698
Interest/NOPBT